Top 5 Biologics Articles of 2024
Check out this list of the top five biologics articles posted on Managed Healthcare Executive this year!
1. 2024 Formulary Moves
The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).
2. PBMs Start to Embrace Biosimilars
Pharmacy benefit managers (PBMs) are slowly coming around and putting biosimilars on their formularies. IQVIA estimates that the dearth of a Humira (adalimumab) biosimilars last year cost patients and employers cumulatively $6 billion.
3. Prolia and Xgeva Biosimilar Companies Are Queuing Up
But Amgen and Sandoz are in a patent fight over the launching of Sandoz's biosimilars to the bone-building drugs.
4. Biologics that Treat Arthritis May Lower Cardiovascular Risk
A recent study has found that biologics may have an effect on arterial wall inflammation and plaque composition, which offsets the influence of joint-derived inflammation in patients with arthritis.
5. New Biosimilars Continue to be Approved But Uptake Varies by Class
A recent IQVIA report found that uptake of biosimilars on the market for at least three years varies from 8% for insulin lispro to 82% for bevacizumab.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
